Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-10T23:50:17.736Z Has data issue: false hasContentIssue false
  • English
  • Français

Receptor mechanisms of antipsychotic drug atypicality

Published online by Cambridge University Press:  16 April 2020

GP Reynolds
GP Reynolds*
Affiliation:
Department of Biomedical Science, University of Sheffield, Sheffield, S10 2TN, UK
Get access

Summary

Recent advances in antipsychotic treatment of schizophrenia have offered several new compounds which avoid many of the limitations of the classical antipsychotics. These so-called ‘atypical’ antipsychotics have fewer extrapyramidal side effects, greater efficacy against negative symptoms and greater efficacy in otherwise treatment-resistant patients. However, the mechanism of action of these atypical antipsychotics is still unclear. The several receptors currently implicated in the pharmacological profile of these atypical antipsychotics include subtypes of those for dopamine, serotonin, noradrenaline, and acetylcholine among others. The current hypotheses for possible mechanisms of action of atypical antipsychotics are discussed along with the experimental correlates of antipsychotic efficacy in animal models.

Keywords

antipsychoticsschizophreniaatypicalityreceptors
Type
Research Article
Information
European Psychiatry , Volume 13 , Issue S1 , 1998 , pp. 5s - 8s
Copyright
Copyright © Elsevier, Pari 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bakshi, V, Geyer, MAAntagonism off P-induced deficits prepulse inhibition by olanzapine (abstract) Soc Neurosci Abstr 1995; 21: 1707Google Scholar
Blake, TJ, Reynolds, G.P.Antipsychotic drug action at α2-adrenoceptor subtypes in postmortem human brain J Psychopharmacol 10 (Suppl) 1996 A7Google Scholar
Corrigan, FM, MacDonald, S, Reynolds, G.P.Clozapine-induced hypersalivation and the alpha 2 adienoceptor Br J Psychiatry 1995; 167: 412CrossRefGoogle Scholar
Farde, L, Nordstrom, AL, Wiesel, FA, Pauli, S, Hallidin, C, Sedvall, GPositron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical antipsychotics and clozapine Arch Gen Psychiatry 1992; 49: 538544CrossRefGoogle ScholarPubMed
Litman, RE, Hong, WW, Weissman, EM, Su, TP, Potter, WZ, Pickar, DIdazoxan, an α2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study J Clin Pharmacol 1993; 13: 264–267Google Scholar
Litman, RE, Su, TP, Potter, WZ, Hong, WW, Pickar, DIdazoxan and response to typical antipsychotics in treatment-resistant schizophrenia. Comparison with the atypical antipsychotic, clozapine Br J Psychiatry 1996; 168: 571–579CrossRefGoogle Scholar
Pilowsky, LS, Busatto, GF, Taylor, M, Costa, DC, Sharma, T, Sigmundsson, T, et al.Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine — a [123I] IBZM single photon emission tomography (SPET) study Psychopharmacol 1996; 124: 148–153CrossRefGoogle Scholar
Reynolds, G.P.Neurotransmitter systems in schizophrenia Int Rev Neurobiol 1995; 28: 305–339CrossRefGoogle Scholar
Reynolds, G.P.The importance of dopamine D4 receptors in the action and development of antipsychotic agents Drugs 1996; 51: 7–11CrossRefGoogle ScholarPubMed
Reynolds, G.P., Czudek, CNew approaches to the drug treatment of schizophrenia Adv Pharmacol 1995; 32: 461–503CrossRefGoogle ScholarPubMed
Robertson, GS, Matsumara, H, Fibiger, HCInduction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity J Pharmacol Exp Ther 1994; 271: 1058–1066Google ScholarPubMed
White, FJ, Wang, RYDifferential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurones Science 1983; 221: 1054–1057CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.